Approval · Notice of Compliance 38209 · 2026
PRO-SUMATRIPTAN: Notice of Compliance 38209
Issued September 1, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38209
- Date
- September 1, 2026
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Change in product name Administrative: Update to labelling (to match Licensor)
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRO-SUMATRIPTAN | 02324652 | Marketed |
| PRO-SUMATRIPTAN | 02324660 | Marketed |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB